S. Ramjug (Altrincham, United Kingdom), A. Boucly (Le Kremlin Bicètre, France)
This session is built from abstracts published on the ERS Congress platform from 23 August, in an e-poster pdf format with a 3-minute audio narration. Participants and chairs of the session are invited to access all e-posters from 23 August to 4 September prior to the 1-hour live, online discussion scheduled from September 5-7. Please note that during live discussion there will be NO e-poster/abstract presentations, only discussion.
Understanding of palliative care among people affected by Pulmonary Hypertension
I. Armstrong (Sheffield, United Kingdom), S. Clayton (Sheffield, United Kingdom), J. Sephton (Sheffield, United Kingdom), J. Smith (Sheffield, United Kingdom), M. Ferguson (Sheffield, United Kingdom)
|  |
Selexipag real-world experience in patients over 75 yrs with pulmonary arterial hypertension (PAH)
S. Gaine (Dublin, Ireland), P. Escribano (Madrid, Spain), P. Biedermann (Allschwil, Switzerland), A. Muller (Allschwil, Switzerland), H. Sun (Allschwil, Switzerland), S. Söderberg (Umeå, Sweden), T. Lange (Regensburg, Germany)
|  |
Switching from PDE5i to riociguat in patients with PAH: A responder analysis from REPLACE
J. Klinger (Providence, RI,, United States of America), R. Benza (Columbus, OH,, United States of America), S. Chang (Gangnam-gu, Seoul,, Republic of Korea), H. Ghofrani (Giessen,, Germany), M. Hoeper (Hannover,, Germany), P. Jansa (Prague,, Czech Republic), J. Ota-Arakaki (São Paulo,, Brazil), S. Rosenkranz (Cologne,, Germany), G. Simonneau (Le Kremlin-Bicêtre,, France), C. Vizza (Rome,, Italy), A. Vonk-Noordegraaf (Amsterdam,, Netherlands), V. Mclaughlin (Ann Arbor, MI,, United States of America)
| |
ELEVATE 2: A multicenter study of rodatristat ethyl in patients with WHO Group 1 pulmonary arterial hypertension (PAH)
H. Lazarus (Cary, NC, United States of America), J. Denning (Cary, NC, United States of America), W. Kamau-Kelley (Cary, NC, United States of America), S. Wring (Cary, NC, United States of America), M. Palacios (Cary, NC, United States of America), M. Humbert (Paris, France)
| |
Acute hemodynamic effect of acetazolamide in patients with pulmonary hypertension whilst breathing normoxic and hypoxic air: a randomized cross-over trial
M. Lichtblau (Zürich, Switzerland), C. Berlier (Zürich, Switzerland), S. Saxer (Zürich, Switzerland), A. Carta (Zürich, Switzerland), L. Mayer (Zürich, Switzerland), A. Groth (Zürich, Switzerland), P. Bader (Zürich, Switzerland), S. Schneider (Zürich, Switzerland), M. Furian (Zürich, Switzerland), E. Schwarz (Zürich, Switzerland), E. Swenson (Seattle, United States of America), K. Bloch (Zürich, Switzerland), S. Ulrich (Zürich, Switzerland)
| |
Predictors of response to phosphodiesterase-5 inhibitors in pulmonary arterial hypertension
A. Garcia (Madrid, Spain), I. Blanco (Madrid, Spain), R. Borras (Barcelona, Spain), M. Lopez-Meseguer (Barcelona, Spain), J. Domingo-Morera (Zaragoza, Spain), C. Martin-Ontiyuelo (Madrid, Spain), O. Tura (Madrid, Spain), I. Otero-Gonzalez (A Coruña, Spain), P. Escribano-Subías (Madrid, Spain), J. Barberà (Madrid, Spain)
| |
Effect of short-term oxygen therapy on exercise performance in patients with cyanotic congenital heart disease
S. Saxer (Zürich, Switzerland), L. Calendo (Zürich, Switzerland), M. Lichtblau (Zürich, Switzerland), J. Müller (Zürich, Switzerland), A. Carta (Zürich, Switzerland), F. Gautschi (Zürich, Switzerland), C. Berlier (Zürich, Switzerland), E. Schwarz (Zürich, Switzerland), K. Bloch (Zürich, Switzerland), M. Greutmann (Zürich, Switzerland), S. Ulrich (Zürich, Switzerland)
| |
Outcomes of patients with decreased arterial oxyhaemoglobin saturation on pulmonary arterial hypertension drugs
S. Valentin (Nancy, France), A. Maurac (Nancy, France), O. Sitbon (Le Kremlin-Bicêtre, France), A. Beurnier (Le Kremlin-Bicêtre, France), E. Gomez (Nancy, France), A. Guillaumot (Nancy, France), L. Textoris (Nancy, France), R. Fay (Nancy, France), L. Savale (Le Kremlin-Bicêtre, France), X. Jaïs (Le Kremlin-Bicêtre, France), D. Montani (Le Kremlin-Bicêtre, France), F. Picard (Pessac, France), J. Mornex (Lyon, France), G. Prevot (Toulouse, France), F. Chabot (Nancy, France), M. Humbert (Le Kremlin-Bicêtre, France), A. Chaouat (Nancy, France)
| |
Critical care outcomes in patients with pre-existing pulmonary hypertension: insights from the ASPIRE registry
R. Condliffe (Sheffield (South Yorkshire), United Kingdom), K. Bauchmuller (Sheffield (South Yorkshire), United Kingdom), J. Southern (Sheffield (South Yorkshire), United Kingdom), C. Billings (Sheffield (South Yorkshire), United Kingdom), A. Charalampopoulos (Sheffield (South Yorkshire), United Kingdom), C. Elliot (Sheffield (South Yorkshire), United Kingdom), A. Hameed (Sheffield (South Yorkshire), United Kingdom), D. Kiely (Sheffield (South Yorkshire), United Kingdom), I. Sabroe (Sheffield (South Yorkshire), United Kingdom), R. Thompson (Sheffield (South Yorkshire), United Kingdom), A. Raithatha (Sheffield (South Yorkshire), United Kingdom), G. Mills (Sheffield (South Yorkshire), United Kingdom)
| |
Prognostic value of renal doppler in acute decompensated precapillary pulmonary hypertension
J. Pichon (Le Kremlin-Bicêtre, France), C. Fauvel (Rouen, France), A. Roche (Le Kremlin-Bicêtre, France), A. Boucly (Le Kremlin-Bicêtre, France), X. Jaïs (Le Kremlin-Bicêtre, France), M. Jevnikar (Le Kremlin-Bicêtre, France), N. Ebstein (Le Kremlin-Bicêtre, France), O. Sitbon (Le Kremlin-Bicêtre, France), D. Montani (Le Kremlin-Bicêtre, France), M. Humbert (Le Kremlin-Bicêtre, France), L. Savale (Le Kremlin-Bicêtre, France)
| |
Gas exchange impairment in COPD with severe pulmonary hypertension
L. Piccari (Barcelona, Spain), I. Blanco (Barcelona, Spain), Y. Torralba (Barcelona, Spain), E. Arismendi (Barcelona, Spain), C. Gistau (Barcelona, Spain), A. Ramírez (Barcelona, Spain), F. Burgos (Barcelona, Spain), J. Moisés (Barcelona, Spain), J. Barberà (Barcelona, Spain)
| |
Effect of phosphodiesterase 5 inhibitor in patients with pulmonary hypertension associated with chronic obstructive pulmonary disease
G. Pavliša (Zagreb, Croatia), L. Ljubicic (Zagreb, Croatia), F. Dzubur (Zagreb, Croatia), M. Jankovic Makek (Zagreb, Croatia), L. Basara (Zagreb, Croatia), M. Samarzija (Zagreb, Croatia)
| |
BREEZE: Open-label, Clinical Study to Evaluate the Safety and Tolerability of a Treprostinil Dry Powder Inhaler in Patients with Pulmonary Arterial Hypertension Currently Using Tyvaso
L. Spikes (Kansas City, United States of America), S. Shapiro (Los Angeles, United States of America), R. Restrepo-Jaramillo (Tampa, United States of America), J. Joly (Birmingham, United States of America), T. Shah (Dallas, United States of America), J. Scoggin (RTP, United States of America), L. Edwards (RTP, United States of America), P. Smith (RTP, United States of America)
| |
A multicompartmemt lung model predicts pulmonary pharmacokinetics of inhaled liposomal treprostinil (L606) in healthy volunteer
P. Kan (Taipei, Taiwan), K. Chen (Taipei, Taiwan)
| |
Drug-drug interaction study between zamicastat and furosemide in healthy subjects
A. Santos (Coronado (S. Mamede e S. Romão) - Porto, Portugal), L. Magalhães (Coronado (S. Mamede e S. Romão) - Porto, Portugal), A. Guimarães (Coronado (S. Mamede e S. Romão) - Porto, Portugal), H. Gama (Coronado (S. Mamede e S. Romão) - Porto, Portugal), P. Magalhaes (Coronado (S. Mamede e S. Romão) - Porto, Portugal), P. Soares-Da-Silva (Porto, Portugal)
| |
Biological quality control and core laboratory considerations for CPET in a clinical trial of ralinepag in patients with pulmonary arterial hypertension: ADVANCE CAPACITY
J. Porszasz (Torrance, United States of America), L. Holdstock (Research Triangle Park, United States of America), S. Blonshine (Mason, United States of America), R. Casaburi (Torrance, United States of America), D. Yehle (Research Triangle Park, United States of America), M. Cunningham (Research Triangle Park, United States of America), J. Blonshine (Mason, United States of America), R. Oudiz (Torrance, United States of America), M. Guazzi (Milan, Italy), F. Torres (Dallas, United States of America), R. Benza (Columbus, United States of America), J. Vachiery (Erasme Academic Hospital, Belgium)
| |
Prospective 3D echocardiographic analysis of RV remodeling and contracility in PH Patients
T. Lambert (Rouen- Le Havre, France), B. Lamia (Rouen- Le Havre, France), A. Picard (Rouen- Le Havre, France), M. Azzi (Rouen- Le Havre, France), F. Bidar (Rouen- Le Havre, France), P. Bonnet (Rouen- Le Havre, France), B. Lamia (Rouen- Le Havre, France)
| |
MRI metric lung parenchyma T1 indicates lung pathology in patients with pulmonary hypertension.
L. Saunders (Sheffield, United Kingdom), D. Capener (Sheffield, United Kingdom), R. Condliffe (Sheffield, United Kingdom), D. Kiely (Sheffield, United Kingdom), J. Wild (Sheffield, United Kingdom), A. Swift (Sheffield, United Kingdom)
| |
Late Breaking Abstract - Implications of new PH definition for CTEPD
A. Reddy (Cambridge, United Kingdom), E. Swietlik (Cambridge, United Kingdom), L. Robertson (Cambridge, United Kingdom), A. Michael (Cambridge, United Kingdom), S. Boyle (Cambridge, United Kingdom), G. Polwarth (Cambridge, United Kingdom), D. Taboada (Cambridge, United Kingdom), C. Hadinnapola (Cambridge, United Kingdom), J. Cannon (Cambridge, United Kingdom), K. Sheares (Cambridge, United Kingdom), M. Toshner (Cambridge, United Kingdom), J. Pepke-Zaba (Cambridge, United Kingdom)
| |